Your browser is no longer supported. Please, upgrade your browser.
Settings
REGN Regeneron Pharmaceuticals, Inc. daily Stock Chart
REGN [NASD]
Regeneron Pharmaceuticals, Inc.
IndexS&P 500 P/E19.41 EPS (ttm)15.13 Insider Own1.20% Shs Outstand106.26M Perf Week-2.67%
Market Cap31.21B Forward P/E13.98 EPS next Y21.01 Insider Trans-2.73% Shs Float77.55M Perf Month-9.33%
Income1.75B PEG1.74 EPS next Q4.60 Inst Own69.80% Short Float3.67% Perf Quarter-9.59%
Sales6.06B P/S5.15 EPS this Y70.80% Inst Trans0.83% Short Ratio3.21 Perf Half Y-24.20%
Book/sh61.01 P/B4.81 EPS next Y11.94% ROA16.30% Target Price376.45 Perf Year-35.54%
Cash/sh15.29 P/C19.21 EPS next 5Y11.16% ROE23.50% 52W Range281.89 - 543.55 Perf YTD-21.87%
Dividend- P/FCF24.61 EPS past 5Y14.30% ROI22.30% 52W High-45.96% Beta1.38
Dividend %- Quick Ratio3.10 Sales past 5Y33.60% Gross Margin92.90% 52W Low4.20% ATR8.63
Employees6200 Current Ratio3.60 Sales Q/Q14.60% Oper. Margin36.50% RSI (14)40.31 Volatility1.92% 3.21%
OptionableYes Debt/Eq0.00 EPS Q/Q92.30% Profit Margin23.50% Rel Volume0.72 Prev Close294.61
ShortableYes LT Debt/Eq0.11 EarningsMay 03 BMO Payout0.00% Avg Volume888.72K Price293.74
Recom2.60 SMA20-1.38% SMA50-6.81% SMA200-22.60% Volume638,239 Change-0.30%
May-04-18Reiterated Canaccord Genuity Hold $356 → $304
Apr-09-18Downgrade Raymond James Outperform → Mkt Perform
Feb-21-18Downgrade Canaccord Genuity Buy → Hold $522 → $356
Jan-09-18Reiterated Citigroup Neutral $380 → $388
Dec-01-17Downgrade Citigroup Buy → Neutral $480 → $380
Nov-09-17Reiterated RBC Capital Mkts Sector Perform $473 → $425
Oct-24-17Resumed Guggenheim Buy $540
Oct-20-17Downgrade Barclays Equal Weight → Underweight $450 → $395
Sep-29-17Resumed Piper Jaffray Overweight $540
Sep-15-17Initiated RBC Capital Mkts Sector Perform $475
Sep-06-17Resumed Raymond James Outperform $566
Aug-17-17Initiated Evercore ISI Outperform $605
Aug-04-17Reiterated UBS Buy $489 → $535
Aug-01-17Downgrade Robert W. Baird Neutral → Underperform $408
Jun-30-17Reiterated BTIG Research Buy $480 → $540
Jun-26-17Downgrade Bernstein Outperform → Mkt Perform
Jun-20-17Reiterated Piper Jaffray Overweight $446 → $557
May-05-17Upgrade Canaccord Genuity Hold → Buy $375 → $484
Mar-29-17Reiterated UBS Buy $435 → $446
Mar-17-17Initiated Oppenheimer Perform
May-23-18 02:29PM  Biotech Stock Roundup: FDA Gives Nod to Amgen's Drugs, EU Approves Exelixis' Cabometyx Zacks
May-22-18 01:39PM  Is Regeneron Pharmaceuticals Incs (NASDAQ:REGN) Balance Sheet Strong Enough To Weather A Storm? Simply Wall St.
May-21-18 02:17PM  Sanofi: New England Journal of Medicine publishes two positive Phase 3 trials showing Dupixent® (dupilumab) improved moderate-to-severe asthma GlobeNewswire
02:15PM  New England Journal of Medicine publishes two positive Phase 3 trials showing Dupixent® (dupilumab) improved moderate-to-severe asthma PR Newswire
02:14PM  New England Journal of Medicine Publishes Two Positive Phase 3 Trials Showing DUPIXENT® (dupilumab) Improved Moderate-to-Severe Asthma PR Newswire
May-18-18 09:30AM  Regeneron Announces Upcoming Investor Conference Presentation PR Newswire
May-17-18 04:41PM  Regeneron: Too 'Legit' To Quit Vs. Merck, Bristol In Lung Cancer Investor's Business Daily
10:00AM  Amgen's (AMGN) Repatha Gains EU Nod to Include Outcomes Data Zacks
May-16-18 05:00PM  Regeneron and Sanofi Share First Positive Clinical Data for Cemiplimab in Advanced Non-small Cell Lung Cancer at ASCO PR Newswire
02:37PM  MARKETS: Russell 2000 hits all-time high; Walmart earnings on deck; oil prices reverse; healthcare stocks in focus Yahoo Finance Video
11:00AM  Sanofi Eczema Drug Dupixent Succeeds in Adolescents Study Zacks
08:00AM  Dupixent® (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitis PR Newswire
01:01AM  Sanofi: Dupixent® (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitis GlobeNewswire
01:01AM  Positive Phase 3 Trial of DUPIXENT® (dupilumab) in Adolescents with Inadequately Controlled Moderate-to-severe Atopic Dermatitis PR Newswire
May-14-18 08:00AM  Todays Research Reports on Stocks to Watch: Regeneron Pharmaceuticals and Synergy Pharmaceuticals ACCESSWIRE
May-11-18 04:36PM  Why The Trade Desk, Noodles & Co., and Regeneron Pharmaceuticals Jumped Today Motley Fool +6.24%
02:08PM  Regeneron Downtrend Ending But No Rush to Buy TheStreet.com
May-10-18 06:31PM  Cramer vets biotech giants Biogen, Celgene, Gilead and Regeneron for positive prospects CNBC
May-08-18 04:15PM  Edited Transcript of REGN earnings conference call or presentation 3-May-18 12:30pm GMT Thomson Reuters StreetEvents
May-07-18 11:34AM  Geisinger to offer DNA sequencing to all its patients American City Business Journals
May-06-18 09:22AM  3 Reasons Regeneron Stock Could Start Climbing Again Motley Fool
May-05-18 09:16AM  2 Beaten-Down Biotech Stocks That Look Like Bargains Now Motley Fool
07:31AM  Are These Disappointing Drugs Back on Track to Billions? Motley Fool
May-04-18 08:16AM  Benzinga's Daily Biotech Pulse: Portola Receives FDA Nod, Mallinckrodt Gets Thumbs Down Benzinga
May-03-18 05:44PM  Regeneron Topples Despite Surprising Beat For Blockbuster Eye Drug Investor's Business Daily
01:45PM  Health Secretary Alex Azar: Bold action is on the way for drug prices CNBC
12:47PM  Regeneron Isnt Changing, for Better or Worse Bloomberg
12:08PM  Regeneron's newer drugs disappoint, shares slip Reuters
11:10AM  Cigna, Regeneron, New York Times and Ferrari post earnings beats Yahoo Finance
10:57AM  MARKETS: Blue Apron stock climbs wall of worry as loss not as great as expected Yahoo Finance Video
10:27AM  Regeneron (REGN) Q1 Earnings Top, Sales Lag, Updates View Zacks
10:23AM  Cigna, Regeneron, New York Times and Ferrari post earnings beats Yahoo Finance Video
10:19AM  Pfizer Inc. Is Stuck in a Trading Range for Now InvestorPlace
09:39AM  Regeneron Pharmaceuticals: Sequencing Its Way to +30% Upside Benzinga
08:51AM  Futures push lower, Tesla and Spotify miss Wall Street expectations Yahoo Finance
08:00AM  Stocks making the biggest moves premarket: CI, BDX, REGN, LOGI, KHC, APRN & more CNBC
06:41AM  Regeneron: 1Q Earnings Snapshot Associated Press
06:34AM  Regeneron's first quarter profit soars 92 percent Reuters
May-02-18 09:23AM  Biotech Stock Roundup: ALXN, VRTX Post Solid Results, GILD Disappoints in Q1 Zacks
08:38AM  Esperion shares plummet 20% on late-stage trial results MarketWatch
May-01-18 04:19PM  Regeneron Is Undercutting Amgen In Cholesterol Drugs Will It Help Share? Investor's Business Daily
01:30PM  Regeneron/Sanofi cut heart drug price to $4,500-$6,600 for Express Scripts Reuters
01:15PM  Allergan plc Stock Becomes a Buy as It Bottoms Out InvestorPlace
10:13AM  Biotech: Better Luck Next Time Barrons.com
09:14AM  Amgen says Express Scripts exclusion impacts 2,000 Repatha patients Reuters
07:19AM  Regeneron and Express Scripts announce exclusive pricing ... CNBC Videos
07:16AM  Sanofi/Regeneron cut Praluent drug price in Express Scripts deal Reuters
07:02AM  Regeneron And Express Scripts Reach A Deal On Embattled Cholesterol Drug Forbes
07:00AM  [$$] Sanofi slashes price of wannabe-blockbuster cholesterol drug Financial Times
07:00AM  Sanofi and Regeneron to lower net price of Praluent® (alirocumab) Injection in exchange for straightforward, more affordable patient access for Express Scripts patients PR Newswire
07:00AM  Regeneron/Sanofi to cut price of heart drug in Express Scripts deal Reuters
07:00AM  Express Scripts to Ease Access to Costly Cholesterol Drug Bloomberg
07:00AM  A $14,000 cholesterol drug gets a price cut as Regeneron, Sanofi strike deal with Express Scripts CNBC
06:59AM  Regeneron and Sanofi to Lower Net Price of Praluent® (alirocumab) Injection in Exchange for Straightforward, More Affordable Patient Access for Express Scripts Patients PR Newswire
Apr-30-18 06:09PM  What's in the Offing for Regeneron (REGN) in Q1 Earnings? Zacks
01:02AM  Sanofi: FDA to Conduct Priority Review of Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma GlobeNewswire
01:00AM  FDA to Conduct Priority Review of Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma PR Newswire
Apr-27-18 04:45PM  Why Regeneron's Quarter 'Won't Be Pretty' For Potential Blockbuster Drug Investor's Business Daily
02:32PM  NYSE trader: Fed, GDP, Consumer Sentiment and that Amazon Prime price hike Yahoo Finance Video
Apr-25-18 12:30PM  Amgen (AMGN) Earnings Beat Estimates in Q1, Revenues Up Y/Y Zacks
Apr-23-18 09:30AM  Regeneron Announces Upcoming Investor Conference Presentations PR Newswire
Apr-18-18 03:59PM  Closing Bell Ringer, April 18, 2018 CNBC Videos
Apr-17-18 11:59AM  AbbVie Inc. Is a Clear Value Play in Biotech Stocks InvestorPlace
Apr-12-18 12:15PM  Oakmark fund manager talks his Q1 buys CNBC Videos
11:48AM  3 Biotech Stocks Analysts Have Been Too Bullish On Investopedia
07:19AM  Is PowerShares Dynamic Biotechnology & Genome Portfolio (PBE) a Hot ETF Right Now? Zacks
Apr-11-18 12:22PM  Vertex Is Worth More Than You Think Barrons.com
Apr-10-18 04:38PM  FDA Restricts Sale of Bayer's Essure Birth Control Device Zacks
01:29PM  Edited Transcript of REGN presentation 6-Mar-17 6:05pm GMT Thomson Reuters StreetEvents
Apr-09-18 05:15PM  FDA Okays Label Expansion of Pacira's Exparel's, Stock Up Zacks
09:30AM  Regeneron to Report First Quarter 2018 Financial and Operating Results and Host Conference Call and Webcast on May 3, 2018 PR Newswire
Apr-06-18 06:32PM  Emergent (EBS) Gains 86.1% in a Year's Time: Here's Why Zacks
05:35PM  Novo Nordisk Obtains Licence for Sickle Cell Disease Program Zacks
Apr-05-18 03:36PM  Catalyst (CPRX) Up on New Drug Application for Firdapse Zacks
07:00AM  Wired News EMA to Review Regenerons Marketing Authorization Application for Cemiplimab ACCESSWIRE
Apr-04-18 11:15AM  Bio-Path Leukemia Combo Study Shows Positive Early Data Zacks
10:56AM  Biotech Stock Roundup: EDGE Falls, ALKS Down, FDA OK's AMGN Drug Label Expansion Zacks
10:30AM  Rigel (RIGL) Sinks on Failure of Mid-Stage Study on Lead Drug Zacks
Apr-03-18 05:28PM  Sanofi's (SNY) Skin Cancer Candidate Filing Accepted in EU Zacks
03:23PM  Alkermes Sinks as FDA Refuses Depression Drug Review Zacks
11:05AM  Celgene (CELG) President and COO to Step Down: What's Ahead? Zacks
11:00AM  EMA Accepts Regeneron/Sanofi's application for Dupixent Zacks
08:44AM  Amgen's (AMGN) Xgeva Gets EU Approval for Expanded Label Zacks
01:22AM  European Medicines Agency to review Sanofi-Regeneron's Dupixent, Cemiplimab Reuters
01:02AM  Sanofi: EMA to review Dupixent® (dupilumab) as potential treatment for inadequately controlled moderate-to-severe asthma GlobeNewswire
01:02AM  Sanofi: EMA to review cemiplimab as a potential treatment for advanced cutaneous squamous cell carcinoma GlobeNewswire
01:01AM  EMA to Review DUPIXENT® (dupilumab) as Potential Treatment for Inadequately Controlled Moderate-to-Severe Asthma PR Newswire
01:00AM  EMA to Review Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma PR Newswire
Apr-02-18 05:43PM  Alnylam Falls on Pfizer's Rare Disease Drug Success Zacks
10:25AM  Edge Therapeutics Loses Edge on Failure of Late-Stage Study Zacks
Mar-29-18 11:00AM  Celgene (CELG) Up on Deal With bluebird For CAR-T Candidate Zacks
09:54AM  BioMarin's MAA for Phenylketonuria Candidate Gains EU Nod Zacks
06:31AM  Is Regeneron Pharmaceuticals, Inc. a Buy? Motley Fool
Mar-28-18 05:34PM  Regeneron CEO 'optimistic' will strike deals to lower $14,000 per-year cholesterol drug CNBC
02:40PM  Regeneron CEO: There are structural issues around drug pr... CNBC Videos
10:50AM  Celgene Loses 17.8% in 3 Months: Time to Reshuffle Portfolio? Zacks
Mar-27-18 02:28PM  Is Regeneron Pharmaceuticals Inc (NASDAQ:REGN) A Sell At Its Current PE Ratio? Simply Wall St.
09:06AM  Add These 7 GARP Stocks to Your Portfolio for Maximum Returns Zacks
09:00AM  Wall Street Has Given Up on These 3 Stocks, and That's a Huge Mistake Motley Fool
Mar-26-18 04:13PM  Roche's Tecentriq Combo Study Meets Co-Primary Endpoint Zacks
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat adult patients with moderate-to-severe atopic dermatitis; Praluent injection, an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and Kevzara solution for subcutaneous injection to treat rheumatoid arthritis in adults. In addition, the company offers ARCALYST injection for cryopyrin-associated periodic syndromes; and ZALTRAP, an injection for intravenous infusion, which is used in combination with 5-fluorouracil, leucovorin, and irinotecan for the treatment of metastatic colorectal cancer. Further, it develops EYLEA, a trap-based clinical product that is in Phase III study for the treatment of neovascular glaucoma; and Dupixent, Praluent, Kevzara, Suptavumab, Cemiplimab, Fasinumab, Evinacumab, Nesvacumab/aflibercept, Trevogrumab, REGN1908-1909, REGN1979, REGN3470-3471-3479, REGN2477, REGN3500, REGN3767, and REGN3918, which are antibody-based clinical programs under various stages of development. The company has collaboration and license agreements with Sanofi, Bayer, Mitsubishi Tanabe Pharma, Teva, Intellia Therapeutics, Adicet Bio, Decibel Therapeutics, Astellas, Alnylam Pharmaceuticals, Inc., and others. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
STAHL NEILEVP Research and DevelopmentMay 24Sale295.0911,4073,366,09231,973May 25 04:03 PM
STAHL NEILEVP Research and DevelopmentMay 23Option Exercise30.6326,736818,92458,709May 25 04:03 PM
SING GEORGE LDirectorMay 10Sale286.6213,0003,726,000114,772May 11 04:02 PM
SING GEORGE LDirectorMay 09Sale285.297,0001,997,030127,772May 11 04:02 PM
GOLDSTEIN JOSEPH LDirectorMar 19Option Exercise57.112,000114,22014,000Mar 19 04:47 PM
GOLDSTEIN JOSEPH LDirectorMar 19Sale350.022,000700,04012,000Mar 19 04:47 PM
GOLDSTEIN JOSEPH LDirectorMar 14Option Exercise57.112,000114,22014,000Mar 14 04:01 PM
GOLDSTEIN JOSEPH LDirectorMar 14Sale340.002,000680,00012,000Mar 14 04:01 PM
GOLDSTEIN JOSEPH LDirectorFeb 09Sale325.601,000325,60012,000Feb 13 04:01 PM
Fenimore Christopher R.VP ControllerJan 16Option Exercise21.251503,188150Jan 17 04:07 PM
SING GEORGE LDirectorJan 02Option Exercise23.8415,000357,600134,772Jan 03 04:13 PM
YANCOPOULOS GEORGEPresident & CSODec 13Option Exercise21.92195,4384,284,001786,786Dec 13 05:17 PM
SCHLEIFER LEONARD SPresident & CEODec 13Option Exercise21.92250,0005,480,000407,409Dec 13 05:17 PM
VAGELOS P ROYChairman of the BoardDec 11Option Exercise21.92153,9693,375,000483,512Dec 13 04:53 PM
BROWN MICHAEL SDirectorOct 05Option Exercise177.821,500266,7301,500Oct 05 04:18 PM
BROWN MICHAEL SDirectorOct 05Sale475.001,500712,5000Oct 05 04:18 PM
BAKER CHARLES ADirectorSep 29Option Exercise18.612,00037,22011,000Oct 03 04:00 PM
BAKER CHARLES ADirectorSep 29Sale450.002,000900,0009,000Oct 03 04:00 PM
Landry Robert ESVP Finance & CFOSep 06Sale497.62474235,8737,099Sep 06 05:06 PM
Landry Robert ESVP Finance & CFOSep 05Sale501.0618994,7007,573Sep 06 05:06 PM
Landry Robert ESVP Finance & CFOSep 01Option Exercise272.703,000818,10010,099Sep 06 05:06 PM
Landry Robert ESVP Finance & CFOAug 31Sale493.43427210,6937,099Sep 01 04:04 PM
Landry Robert ESVP Finance & CFOAug 30Option Exercise272.702,000545,4009,099Sep 01 04:04 PM
Landry Robert ESVP Finance & CFOAug 23Sale476.45468222,9817,099Aug 24 04:47 PM
Landry Robert ESVP Finance & CFOAug 22Option Exercise272.702,000545,4009,099Aug 24 04:47 PM
VAGELOS P ROYChairman of the BoardAug 22Sale477.6431,94415,257,816329,543Aug 23 04:21 PM
VAGELOS P ROYChairman of the BoardAug 21Sale470.3224,26911,414,076361,487Aug 23 04:21 PM
VAGELOS P ROYChairman of the BoardAug 18Sale470.152,9001,363,435385,756Aug 18 05:00 PM
VAGELOS P ROYChairman of the BoardAug 17Sale470.001,305613,350388,656Aug 18 05:00 PM
VAGELOS P ROYChairman of the BoardAug 16Option Exercise21.92153,9693,375,000483,512Aug 18 05:00 PM
VAGELOS P ROYChairman of the BoardAug 16Sale470.1710,9865,165,288389,961Aug 18 05:00 PM
Terifay Robert JEVP CommercialAug 10Option Exercise52.031,92199,95025,214Aug 11 04:02 PM
Landry Robert ESVP Finance & CFOAug 08Sale472.19526248,3727,099Aug 09 04:03 PM
Landry Robert ESVP Finance & CFOAug 07Option Exercise272.702,000545,4009,099Aug 09 04:03 PM
STAHL NEILEVP Research and DevelopmentJun 22Sale532.558,3064,423,33223,950Jun 23 04:09 PM
Aberman Michael SSVP Strategy Investor RelationJun 22Sale532.422,2691,208,0614,693Jun 23 04:10 PM
STAHL NEILEVP Research and DevelopmentJun 21Option Exercise30.6320,000612,60043,950Jun 23 04:09 PM
Aberman Michael SSVP Strategy Investor RelationJun 21Option Exercise30.634,500137,8359,193Jun 23 04:10 PM
BROWN MICHAEL SDirectorJun 20Option Exercise177.823,000533,4603,000Jun 21 04:11 PM
GOLDSTEIN JOSEPH LDirectorJun 20Option Exercise273.671,000273,67014,000Jun 21 04:12 PM
BROWN MICHAEL SDirectorJun 20Sale500.003,0001,500,0000Jun 21 04:11 PM
GOLDSTEIN JOSEPH LDirectorJun 20Sale500.011,000500,01013,000Jun 21 04:12 PM
Terifay Robert JEVP CommercialJun 16Sale468.1921,1479,900,81423,293Jun 19 04:44 PM
Terifay Robert JEVP CommercialJun 15Option Exercise52.0348,7502,536,46372,043Jun 19 04:44 PM
STAHL NEILEVP Research and DevelopmentJun 15Sale468.458,5674,013,17723,950Jun 16 04:36 PM
STAHL NEILEVP Research and DevelopmentJun 14Option Exercise21.2520,295431,26944,245Jun 16 04:36 PM
BROWN MICHAEL SDirectorJun 12Option Exercise177.822,000355,6402,000Jun 14 04:36 PM
BROWN MICHAEL SDirectorJun 12Sale474.452,000948,8900Jun 14 04:36 PM
GOLDSTEIN JOSEPH LDirectorJun 09Option Exercise273.671,000273,67014,000Jun 13 05:06 PM
GOLDSTEIN JOSEPH LDirectorJun 09Sale482.551,000482,55013,000Jun 13 05:06 PM
STAHL NEILEVP Research and DevelopmentJun 02Sale479.492,8121,348,31423,950Jun 05 04:52 PM
STAHL NEILEVP Research and DevelopmentJun 01Option Exercise198.3810,5442,091,72430,814Jun 05 04:52 PM